In the intricate landscape of drug development, pharmaceutical companies grapple with the complexity of swiftly advancing potential drugs through their pipeline.
The first hurdle for a new drug is ensuring that the preclinical candidate has the optimal properties for success, including pharmacology, metabolism and pharmacokinetic and in vitro safety profiling. The added complexity of achieving this through inhalation can pose many additional challenges.
Our solutions are designed to precisely address these pivotal checkpoints in human and lung-relevant in vitro systems, offering pharmaceutical companies insights that not only expedite the drug development process but also elevate the chances of clinical success.
Models like ImmuPHAGE™ and ImmuLUNG™ are ideal, cost-effective and human-relevant solutions. Our models provide reliable and reproducible representations of alveolar macrophages in the human airways, reducing reliance on animal testing. When applied in conventional screening assessments and together with our cell painting assays, these models support early identification of species differences (rats, humans) in alveolar macrophage responses to support better interpretation of in vivo studies and de-risk drug candidate selection.
Pharmacokinetics & pharmacodynamics
Our expertise includes:
A pharmaceutical company reached out to ImmuONE, searching for a high-throughput model to predict lung-relevant inflammatory reactions upon inhalation of their panel of drugs. Their challenge was twofold. They were seeking a solution that was not only endpoint agnostic, but also robust enough to discern whether inhaled compounds were likely to be safe or might trigger adverse reactions, as seen in in vivo studies.
After in-depth discussions with the company to understand their specific needs, we embarked on an exploratory journey using our novel multiparameter high-content image analysis approach. Our primary objective was to determine if our method had the potential to predict the safety of their inhaled compounds, especially focusing on its ability to predict any adverse inflammatory effects. By employing this advanced technique, we aimed to provide a comprehensive understanding of the potential risks and benefits associated with their inhaled modalities.
This study demonstrated that our multiparameter HCIA tool had the ability to distinguish alveolar macrophage responses in vitro to compounds with different safety profiles. By clearly differentiating between compounds that were safe for inhalation and those posing potential risks, our approach empowered the company to make more informed, timely decisions, thereby streamlining their development process and ensuring a higher degree of safety and reliability.